Drug intelligence / Profile preview

DCR-PDL1

Development stage: Phase 1
Lead developer: Novo Nordisk
Modality: Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
Administration: Intravenous

Overview

DCR-PDL1 is an investigational small interfering RNA (siRNA) therapeutic developed by Dicerna Pharmaceuticals (a subsidiary of Novo Nordisk) for the treatment of solid tumors. It utilizes RNA interference to target and modulate the expression of programmed death-ligand 1 (PD-L1), a protein involved in tumor immune evasion. By silencing PD-L1, DCR-PDL1 aims to enhance anti-tumor immune responses. The drug is currently in Phase 1 clinical trials for patients with advanced or metastatic solid tumors[1][2][3].

Other names: DCR PDL1

Targets

CD274 (Programmed cell death protein 1 ligand 1)

Beyond the preview

Go deeper on DCR-PDL1.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on DCR-PDL1.

Explore the full profile